Abbott Laboratories (ABT) fundamentals: P/E, valuation, undervalued?
Abbott Laboratories · Health Care · ref. ETF XLV · price $102.61
In short — Abbott Laboratories trades at 33.1× earnings (P/E), 16.9× forward, with a net margin of 11.6 % and revenue growth of +13 %. Read: Fairly valued (P/E 17 in line with ~13% growth (PEG 1.3)).
Is Abbott Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$102.61-23.0% over range
Oct 14, 25low $82.56 · high $133.27Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 18 analysts
Valuation : Fairly valued — P/E 17 in line with ~13% growth (PEG 1.3)
Valuation
33.1
P/E (price/earnings)
16.9
Forward P/E
—
PEG
3.5
Price/book (P/B)
$178.7B
Market cap
3.10
EPS
Profitability & growth
11.6 %
Net margin
+13 %
Revenue growth
-48 %
Earnings growth
$32.7B
Total debt
Abbott Laboratories income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $43.7B | $6.9B | 15.9 % |
| 2023 | $40.1B | $5.7B | 14.3 % |
| 2024 | $42.0B | $13.4B | 31.9 % |
| 2025 | $44.3B | $6.5B | 14.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Abbott Laboratories's P/E and is the stock undervalued? What's a good P/E?
Abbott Laboratories's P/E is 33.1 (forward 16.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Abbott Laboratories profitable?
Abbott Laboratories has a net margin of 11.6 % (EPS 3.10). The company is profitable.
Is ABT stock expensive?
Our read: "Fairly valued" — P/E 17 in line with ~13% growth (PEG 1.3). Cross-check with growth and sector.
💬 A question about Abbott Laboratories? The JPI assistant answers using our backtest data.